Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 3/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429431 | 0.91 | SLC6A4 (0.34) | HRH3ACHECSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL3429184 | 0.88 | HRH3 (0.39) | HRH3ACHECSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL3429433 | 0.84 | ACHE (0.35) | HRH3ACHECSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL3429541 | 0.84 | SIGMAR1 (0.33) | ACHEHTR4CHRM4 | |
| SCHEMBL2115787 | 0.81 | HRH3 (0.40) | HRH3ACHEGNAO1SLC6A4SLC6A3 | |
| SCHEMBL3434049 | 0.80 | LPAR3 (0.37) | CSNK2A2CSNK2BCSNK2A1CSNK2A3LPAR3 | |
| SCHEMBL3428614 | 0.79 | GRIN2D (0.31) | — | |
| SCHEMBL27511817 | 0.76 | ENPP1 (0.34) | CHRM4 | |
| SCHEMBL3424280 | 0.75 | ACHE (0.45) | HRH3ACHEGNAO1SLC6A4SLC6A3 | |
| SCHEMBL3430974 | 0.74 | FBP1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | AURKA, AURKC, AURKB | HRH3 2418/4885ACHE 4044/4885CSNK2A2 51/4885 |
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | HRH3 1333/4885ACHE 2078/4885CSNK2A2 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.